SCHEMBL16153929

SCHEMBL16153929

O=C(NC1[C@@H](OCc2ccccc2)OC(CO)[C@@H](O)[C@@H]1O[C@@H]1OC(CO)[C@H](O)[C@H](O)C1O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 2/20 0.52
▸ LGALS8 O00214 1/20 0.51
▸ FGF1 P05230 1/20 0.50
▸ FGF2 P09038 1/20 0.50
▸ VEGFA P15692 1/20 0.50
▸ HPSE Q9Y251 1/20 0.50
▸ MAG P20916 1/20 0.48
▸ SYNJ2 O15056 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ ALPL P05186 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ ALPI P09923 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ ALPG P10696 1/20 0.46
▸ PABPC1 P11940 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ GALK1 P51570 1/20 0.46
▸ CASP7 P55210 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10524869 0.92 LGALS8 (0.54) SLC6A2LGALS8MAGLGALS3
SCHEMBL7768969 0.89 LGALS8 (0.51) SLC6A2LGALS8SYNJ2KDM4EABL1
SCHEMBL16153923 0.89 MAG (0.58) SLC6A2LGALS8FGF1FGF2VEGFA
SCHEMBL542355 0.89 MAG (0.58) SLC6A2LGALS8FGF1FGF2VEGFA
SCHEMBL7717946 0.89 MAG (0.58) SLC6A2LGALS8FGF1FGF2VEGFA
SCHEMBL7717956 0.89 MAG (0.58) SLC6A2LGALS8FGF1FGF2VEGFA
SCHEMBL542353 0.89 MAG (0.58) SLC6A2LGALS8FGF1FGF2VEGFA
SCHEMBL16153928 0.86 SLC6A2 (0.50) SLC6A2LGALS8FGF1FGF2VEGFA
SCHEMBL16153922 0.86 SLC6A2 (0.50) SLC6A2LGALS8FGF1FGF2VEGFA
SCHEMBL12812851 0.85 TACR2 (0.47) SLC6A2LGALS8POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140303363-A1 Preparation and Use of Isolactosamine and Intermediates therefor GLYCOM A/S (DK) 2014-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303363-A1 Preparation and Use of Isolactosamine and Intermediates therefor GALE, B4GALT1, GNE SLC6A2 3154/4885LGALS8 26/4885FGF1 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback